首页>投融资
Maze Therapeutics
D轮
Maze Therapeutics is a biotechnology company focused on developing gene therapies for the potential treatment of cardiovascular and renal disease, including chronic kidney disease and autosomal dominant polycystic kidney disease, metabolic and neurological disorders, including Pompe's disease and amyotrophic lateral sclerosis and eye diseases, including glaucoma and age-related macular degeneration.In January 2022, the company announced a USD 190 million financing.In February 2019, the company raised USD 191 million through financing
基本信息
-
公司全称Maze Therapeutics Inc
-
类型遗传病治疗药物研发商
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数15~50人
-
地址171 Oyster Point Blvd,Suite 200 SOUTH SAN FRANCISCO CALIFORNIA 94080; US; Telephone: +16508505070;
-
联系电话(650) 850-5070
-
邮箱info@mazetx.com
-
成立时间2018-01-01
投融资
-
2024-12-03D轮1.15亿美元Deep Track CapitalFrazier ManagementJanus Henderson InvestorsLogos CapitalThird Rock VenturesARCH Venture PartnersMatrix Capital ManagementGVGeneral CatalystAndreessen HorowitzForesite CapitalWoodline PartnersCasdin CapitalMoore Strategic Ventures
-
2022-01-10未公开1.9亿美元Matrix Capital ManagementTimefolio CapitalTMCPMoore Strategic VenturesDriehaus Capital ManagementForesite CapitalCity Hill VenturesCasdin CapitalWoodline Partnersa16z Bio+HealthGeneral Catalyst
-
2019-10-23未透露未透露City Hill Ventures
-
2019-02-28A轮1.91亿美元Alexandria Venture InvestmentsThird Rock VenturesCasdin CapitalARCH Venture PartnersForesite Capital
- 加载更多
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国)：Veradermics是一家位于美国的生物技术公司，专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台，开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息